Bone toxicity is a well-known side effect of several antiviral agents. In a cohort of virologically suppressed HIV-infected patients, we investigated the effects of a lamivudine/dolutegravir dual therapy on bone mineral density (BMD). We observed a significant improvement in lumbar spine BMD as well as T-score after 12 months of observation with concomitant bisphosphonate therapy independently predicting a greater improvement. These preliminary data show a favorable effect of this 2-drug regimen on bone health.

Ciccullo, A., D'avino, A., Lassandro, A. P., Baldin, G., Borghetti, A., Dusina, A., Emiliozzi, A., Gagliardini, R., Moschese, D., Belmonti, S., Lombardi, F., Di Giambenedetto, S., Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice, <<LE INFEZIONI IN MEDICINA>>, 2019; 26 (4): 336-340 [http://hdl.handle.net/10807/140090]

Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice

Ciccullo, Arturo;Baldin, Gianmaria;Dusina, Alex;Emiliozzi, Arianna;Moschese, Davide;Lombardi, Francesca;Di Giambenedetto, Simona
2018

Abstract

Bone toxicity is a well-known side effect of several antiviral agents. In a cohort of virologically suppressed HIV-infected patients, we investigated the effects of a lamivudine/dolutegravir dual therapy on bone mineral density (BMD). We observed a significant improvement in lumbar spine BMD as well as T-score after 12 months of observation with concomitant bisphosphonate therapy independently predicting a greater improvement. These preliminary data show a favorable effect of this 2-drug regimen on bone health.
Inglese
Ciccullo, A., D'avino, A., Lassandro, A. P., Baldin, G., Borghetti, A., Dusina, A., Emiliozzi, A., Gagliardini, R., Moschese, D., Belmonti, S., Lombardi, F., Di Giambenedetto, S., Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice, <<LE INFEZIONI IN MEDICINA>>, 2019; 26 (4): 336-340 [http://hdl.handle.net/10807/140090]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/140090
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 12
  • ???jsp.display-item.citation.isi??? ND
social impact